Logo image of AXSM

AXSOME THERAPEUTICS INC (AXSM) Stock Fundamental Analysis

NASDAQ:AXSM - Nasdaq - US05464T1043 - Common Stock - Currency: USD

103  -1.46 (-1.4%)

After market: 103 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AXSM. AXSM was compared to 198 industry peers in the Pharmaceuticals industry. AXSM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. AXSM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AXSM has reported negative net income.
In the past year AXSM has reported a negative cash flow from operations.
In the past 5 years AXSM always reported negative net income.
In the past 5 years AXSM always reported negative operating cash flow.
AXSM Yearly Net Income VS EBIT VS OCF VS FCFAXSM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

AXSM's Return On Assets of -50.52% is on the low side compared to the rest of the industry. AXSM is outperformed by 60.61% of its industry peers.
The Return On Equity of AXSM (-503.76%) is worse than 77.27% of its industry peers.
Industry RankSector Rank
ROA -50.52%
ROE -503.76%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AXSM Yearly ROA, ROE, ROICAXSM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

With an excellent Gross Margin value of 91.37%, AXSM belongs to the best of the industry, outperforming 94.44% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for AXSM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AXSM Yearly Profit, Operating, Gross MarginsAXSM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

AXSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
AXSM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AXSM Yearly Shares OutstandingAXSM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
AXSM Yearly Total Debt VS Total AssetsAXSM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 2.80 indicates that AXSM is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.80, AXSM is doing good in the industry, outperforming 76.26% of the companies in the same industry.
A Debt/Equity ratio of 3.22 is on the high side and indicates that AXSM has dependencies on debt financing.
The Debt to Equity ratio of AXSM (3.22) is worse than 80.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.22
Debt/FCF N/A
Altman-Z 2.8
ROIC/WACCN/A
WACC9.78%
AXSM Yearly LT Debt VS Equity VS FCFAXSM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

AXSM has a Current Ratio of 2.11. This indicates that AXSM is financially healthy and has no problem in meeting its short term obligations.
AXSM has a Current ratio (2.11) which is comparable to the rest of the industry.
A Quick Ratio of 2.04 indicates that AXSM has no problem at all paying its short term obligations.
AXSM has a Quick ratio (2.04) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.11
Quick Ratio 2.04
AXSM Yearly Current Assets VS Current LiabilitesAXSM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for AXSM have decreased strongly by -15.19% in the last year.
Looking at the last year, AXSM shows a very strong growth in Revenue. The Revenue has grown by 42.53%.
EPS 1Y (TTM)-15.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.96%
Revenue 1Y (TTM)42.53%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%66.03%

3.2 Future

The Earnings Per Share is expected to grow by 39.63% on average over the next years. This is a very strong growth
Based on estimates for the next years, AXSM will show a very strong growth in Revenue. The Revenue will grow by 46.73% on average per year.
EPS Next Y44.55%
EPS Next 2Y53.02%
EPS Next 3Y52.36%
EPS Next 5Y39.63%
Revenue Next Year61.05%
Revenue Next 2Y62.49%
Revenue Next 3Y58.11%
Revenue Next 5Y46.73%

3.3 Evolution

AXSM Yearly Revenue VS EstimatesAXSM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
AXSM Yearly EPS VS EstimatesAXSM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AXSM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AXSM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AXSM Price Earnings VS Forward Price EarningsAXSM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 -30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AXSM Per share dataAXSM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as AXSM's earnings are expected to grow with 52.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y53.02%
EPS Next 3Y52.36%

More info and screens

0

5. Dividend

5.1 Amount

AXSM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AXSOME THERAPEUTICS INC

NASDAQ:AXSM (4/21/2025, 8:00:01 PM)

After market: 103 0 (0%)

103

-1.46 (-1.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-18 2025-02-18/bmo
Earnings (Next)05-05 2025-05-05/bmo
Inst Owners75.65%
Inst Owner Change1.75%
Ins Owners1.43%
Ins Owner Change0.56%
Market Cap5.02B
Analysts85.22
Price Target180.41 (75.16%)
Short Float %14.34%
Short Ratio5.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-20.92%
Min EPS beat(2)-48.67%
Max EPS beat(2)6.83%
EPS beat(4)1
Avg EPS beat(4)-20.49%
Min EPS beat(4)-48.67%
Max EPS beat(4)6.83%
EPS beat(8)2
Avg EPS beat(8)-13.96%
EPS beat(12)4
Avg EPS beat(12)-9.76%
EPS beat(16)8
Avg EPS beat(16)-4.68%
Revenue beat(2)1
Avg Revenue beat(2)1.38%
Min Revenue beat(2)-1.03%
Max Revenue beat(2)3.79%
Revenue beat(4)2
Avg Revenue beat(4)0.35%
Min Revenue beat(4)-1.69%
Max Revenue beat(4)3.79%
Revenue beat(8)6
Avg Revenue beat(8)34.29%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.14%
PT rev (3m)34.57%
EPS NQ rev (1m)0.16%
EPS NQ rev (3m)-34.96%
EPS NY rev (1m)-37.95%
EPS NY rev (3m)-56.19%
Revenue NQ rev (1m)-0.09%
Revenue NQ rev (3m)0.01%
Revenue NY rev (1m)-0.73%
Revenue NY rev (3m)-3.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.02
P/FCF N/A
P/OCF N/A
P/B 88.11
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.99
EYN/A
EPS(NY)-3.32
Fwd EYN/A
FCF(TTM)-2.64
FCFYN/A
OCF(TTM)-2.63
OCFYN/A
SpS7.91
BVpS1.17
TBVpS-0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -50.52%
ROE -503.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.37%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 3.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.39%
Cap/Sales 0.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.11
Quick Ratio 2.04
Altman-Z 2.8
F-Score3
WACC9.78%
ROIC/WACCN/A
Cap/Depr(3y)9.27%
Cap/Depr(5y)133.06%
Cap/Sales(3y)0.56%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.96%
EPS Next Y44.55%
EPS Next 2Y53.02%
EPS Next 3Y52.36%
EPS Next 5Y39.63%
Revenue 1Y (TTM)42.53%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%66.03%
Revenue Next Year61.05%
Revenue Next 2Y62.49%
Revenue Next 3Y58.11%
Revenue Next 5Y46.73%
EBIT growth 1Y-21.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year57.46%
EBIT Next 3Y61.47%
EBIT Next 5Y46.77%
FCF growth 1Y11.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.49%
OCF growth 3YN/A
OCF growth 5YN/A